Tara Graff, DO, Talks About Acalabrutinib and How the CLL Treatment Landscape has Evolved

01/01/2021

In this video, Dr Graff, Mission Cancer and Blood, Des Moines, Iowa, talks about how the treatment landscape for chronic lymphocytic leukemia (CLL) has evolved in recent years, especially with the introduction of acalabrutinib (Calquence; AstraZeneca).

Recent News

News

Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise

01/29/2026

Stephanie Holland

Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...

Results from a real-world...

01/29/2026

Oncology

News

Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer

01/29/2026

Emily Estrada

The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.

The addition of elenagen to...

01/29/2026

Oncology

News

Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma

01/28/2026

Stephanie Holland

Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.

Results from the phase 1/2...

01/28/2026

Oncology

News

Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer

01/27/2026

Gina Tomaine

Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.

Antibody-based therapies are...

01/27/2026

Oncology

News

Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial

01/27/2026

Emily Estrada

Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.

Tucatinib plus trastuzumab...

01/27/2026

Oncology

News

TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC

01/27/2026

Emily Estrada

A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.

A TOMOX-bevacizumab combination...

01/27/2026

Oncology

News

ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC

01/27/2026

Gina Tomaine

A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.

A translational study identified...

01/27/2026

Oncology

News

CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT

01/26/2026

Gina Tomaine

Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.

Systemic CSF-1R inhibition...

01/26/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer

01/22/2026

Stephanie Holland

Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...

Results from the phase 3...

01/22/2026

Oncology

News

Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer

01/21/2026

Stephanie Holland

Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...

Results from a multicenter,...

01/21/2026

Oncology